Journal of Urology Publishes Outperformance of Cxbladder in US Covid-19 Setting
Pacific Edge is pleased to announce that the American Urological Association’s (AUA) Journal of Urology has published a real world lookback highlighting the clinical utility of Cxbladder in a Covid-19 setting for the management of patients outside the clinic. The lookback study concluded that the use of Cxbladder Monitor and Pacific Edge’s Patient-In-Home Sampling System by physicians reduced the number of cystoscopies required, and that it was both feasible and safe for patients being monitored for urothelial cancer during the Covid-19 pandemic. In addition, the study concluded that Cxbladder could be used to further stratify low risk patients for decreased surveillance during the pandemic and beyond.
The evaluation and lookback was performed by the University of California San Francisco (UCSF) on a cohort of 52 patients who were being monitored for urothelial cancer as part of their standard of care. Cxbladder Monitor correctly identified those at high risk who immediately underwent cystoscopy. Those patients with low Cxbladder Monitor scores were deemed to be low risk and their cystoscopies were deferred to their next scheduled surveillance visit. The follow-up surveillance cystoscopy for these patients, showed no suspicious tumors and no positive cytology was detected. Cxbladder Monitor missed no tumors and among those detected, several were high impact tumors.
CEO of Pacific Edge, David Darling, said: “This latest published evidence provides real-world insight into the effectiveness of Cxbladder in helping to manage patients who can’t come in to the clinic. It is great to see our Patient In-Home Sampling System (PIHSS) being used to such great effect and with such compelling results.
“The COVID-19 pandemic has brought unprecedented changes to the provision of urologic care in order to minimise the risk of transmission. Advances in telemedicine look to be providing a new paradigm for healthcare, and Cxbladder and our Patient-In-Home Sampling System are well positioned to continue as an integral part in the detection and management of patients with urothelial cancer.”
The clinical paper was authored by Carrisa Chu, Kevin Li, Maxwell Meng and Sima Porten and published in the September 2021 issue of the Journal of Urology.
Review the study.« Back